Literature DB >> 31767744

Enterotoxins can support CAR T cells against solid tumors.

Bianca von Scheidt1, Minyu Wang1,2, Amanda J Oliver1,2, Jack D Chan1,2, Metta K Jana2, Aesha I Ali1,2, Fiona Clow3,4, John D Fraser3,4, Kylie M Quinn5,6, Phillip K Darcy1,2, Michael H Kershaw7,2, Clare Y Slaney7,2.   

Abstract

Responses of solid tumors to chimeric antigen receptor (CAR) T cell therapy are often minimal. This is potentially due to a lack of sustained activation and proliferation of CAR T cells when encountering antigen in a profoundly immunosuppressive tumor microenvironment. In this study, we investigate if inducing an interaction between CAR T cells and antigen-presenting cells (APCs) in lymphoid tissue, away from an immunosuppressive microenvironment, could enhance solid-tumor responses. We combined CAR T cell transfer with the bacterial enterotoxin staphylococcal enterotoxin-B (SEB), which naturally links a proportion of T cell receptor (TCR) Vβ subtypes to MHC-II, present on APCs. CAR T cell proliferation and function was significantly enhanced by SEB. Solid tumor-growth inhibition in mice was increased when CAR T cells were administered in combination with SEB. CAR T cell expansion in lymphoid tissue was demonstrated, and inhibition of lymphocyte egress from lymph nodes using FTY720 abrogated the benefit of SEB. We also demonstrate that a bispecific antibody, targeting a c-Myc tag on CAR T cells and cluster of differentiation 40 (CD40), could also enhance CAR T cell activity and mediate increased antitumor activity of CAR T cells. These model systems serve as proof-of-principle that facilitating the interaction of CAR T cells with APCs can enhance their ability to mediate antitumor activity.

Entities:  

Keywords:  CAR T cells; antigen-presenting cells; costimulation; engraftment; superantigen

Mesh:

Substances:

Year:  2019        PMID: 31767744      PMCID: PMC6911243          DOI: 10.1073/pnas.1904618116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases.

Authors:  Thorsten R Mempel; Sarah E Henrickson; Ulrich H Von Andrian
Journal:  Nature       Date:  2004-01-08       Impact factor: 49.962

2.  Antigen targeting to major histocompatibility complex class II with streptococcal mitogenic exotoxin Z-2 M1, a superantigen-based vaccine carrier.

Authors:  Fiona J Radcliff; Jacelyn M S Loh; Birgit Ha; Diana Schuhbauer; James McCluskey; John D Fraser
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

3.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors:  Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  J Clin Oncol       Date:  2017-07-17       Impact factor: 44.544

4.  Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.

Authors:  T Herrmann; J L Maryanski; P Romero; B Fleischer; H R MacDonald
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

5.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Authors:  James N Kochenderfer; Mark E Dudley; Robert O Carpenter; Sadik H Kassim; Jeremy J Rose; William G Telford; Frances T Hakim; David C Halverson; Daniel H Fowler; Nancy M Hardy; Anthony R Mato; Dennis D Hickstein; Juan C Gea-Banacloche; Steven Z Pavletic; Claude Sportes; Irina Maric; Steven A Feldman; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Bipulendu Jena; Michael R Bishop; Ronald E Gress; Steven A Rosenberg
Journal:  Blood       Date:  2013-09-20       Impact factor: 22.113

6.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Authors:  David S Ritchie; Paul J Neeson; Amit Khot; Stefan Peinert; Tsin Tai; Kellie Tainton; Karen Chen; Mandy Shin; Dominic M Wall; Dirk Hönemann; Peter Gambell; David A Westerman; Javier Haurat; Jennifer A Westwood; Andrew M Scott; Lucy Kravets; Michael Dickinson; Joseph A Trapani; Mark J Smyth; Phillip K Darcy; Michael H Kershaw; H Miles Prince
Journal:  Mol Ther       Date:  2013-07-08       Impact factor: 11.454

7.  CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.

Authors:  R M Kedl; M Jordan; T Potter; J Kappler; P Marrack; S Dow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

8.  Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.

Authors:  Jamie Honeychurch; Martin J Glennie; Peter W M Johnson; Timothy M Illidge
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

9.  Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Authors:  Rafael Winograd; Katelyn T Byrne; Rebecca A Evans; Pamela M Odorizzi; Anders R L Meyer; David L Bajor; Cynthia Clendenin; Ben Z Stanger; Emma E Furth; E John Wherry; Robert H Vonderheide
Journal:  Cancer Immunol Res       Date:  2015-02-12       Impact factor: 11.151

10.  Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor.

Authors:  C R Hewitt; J R Lamb; J Hayball; M Hill; M J Owen; R E O'Hehir
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  10 in total

1.  Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells.

Authors:  Jack D Chan; Bianca von Scheidt; Bijun Zeng; Amanda J Oliver; Ashleigh S Davey; Aesha I Ali; Ranjeny Thomas; Joseph A Trapani; Phillip K Darcy; Michael H Kershaw; Riccardo Dolcetti; Clare Y Slaney
Journal:  Clin Transl Immunology       Date:  2020-07-22

Review 2.  Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.

Authors:  Daniela Gm Tantalo; Amanda J Oliver; Bianca von Scheidt; Aaron J Harrison; Scott N Mueller; Michael H Kershaw; Clare Y Slaney
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 3.  CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.

Authors:  Alba Rodriguez-Garcia; Asis Palazon; Estela Noguera-Ortega; Daniel J Powell; Sonia Guedan
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

4.  Innovative approaches to immunotherapy in breast cancer.

Authors:  Kylie M Quinn
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

5.  Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer.

Authors:  Peng Luo; Clare Y Slaney; Jian Zhang
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

6.  Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.

Authors:  Yajun Zhang; Pei Wang; Tengjiao Wang; Yuan Fang; Yongmei Ding; Qijun Qian
Journal:  J Transl Med       Date:  2021-02-18       Impact factor: 5.531

7.  Editorial: Understanding and Engineering Antibody-Superantigen Interactions.

Authors:  Samuel Ken-En Gan; Jeremy P Derrick; Franca Fraternali
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

Review 8.  Superantigen Recognition and Interactions: Functions, Mechanisms and Applications.

Authors:  Anthony M Deacy; Samuel Ken-En Gan; Jeremy P Derrick
Journal:  Front Immunol       Date:  2021-09-20       Impact factor: 7.561

Review 9.  Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers.

Authors:  Aaron J Harrison; Xin Du; Bianca von Scheidt; Michael H Kershaw; Clare Y Slaney
Journal:  Immunother Adv       Date:  2021-07-31

10.  Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.

Authors:  Peter Kar Han Lau; Carleen Cullinane; Susan Jackson; Rachael Walker; Lorey K Smith; Alison Slater; Laura Kirby; Riyaben P Patel; Bianca von Scheidt; Clare Y Slaney; Grant A McArthur; Karen E Sheppard
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.